Skip to main content
SpringerLink
Log in

Are new therapies for faecal incontinence cost effective?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. funding provided by Salix Pharmaceuticals (the manufacturer of NASHA/Dx)

Reference

  • Bernstein MA, et al. Three-Year Cost-effectiveness Model for Non-Animal Stabilized Hyaluronic Acid and Dextranomer Copolymer Compared With Sacral Nerve Stimulation After Conservative Therapy for the Management of Fecal Incontinence. Clinical Therapeutics : 8 May 2014. Available from: URL: http://doi.org/10.1016/j.clinthera.2014.04.010

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Are new therapies for faecal incontinence cost effective?. PharmacoEcon Outcomes News 703, 3 (2014). https://doi.org/10.1007/s40274-014-1250-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1250-z

Search

Navigation